The effect of entrectinib/Luo Shengquan in the treatment of lung cancer

The outstanding value of Entrectinib in the treatment of non-small cell lung cancer (NSCLC) is mainly reflected in its efficacy in ROS1-positive patients. ROS1 fusion gene is an important type of driver mutation. Although the proportion in lung cancer patients is not high, once it occurs, it can significantly promote the progression of tumors. Entrectinib effectively prevents abnormal proliferation and metastasis of cancer cells by targeting the ROS1 signaling pathway, making it an important treatment option for such patients.

Compared with traditional chemotherapy, entrectinib generally leads to faster lesion shrinkage and more durable disease control in ROS1-positive lung cancer. At the same time, because it is designed to penetrate the blood-brain barrier, it also shows clinical value for patients with brain metastases, which distinguishes it from some early targeted drugs. For patients, this means that not only lung lesions can be controlled, but the progression of brain metastases may also be delayed, thereby improving the overall quality of life.

In addition toROS1-positive lung cancer, entrectinib can also be used in patients with NTRK gene fusion-positive lung cancer. Although the proportion of such patients is lower, due to its highly specific mechanism, entrectinib also shows considerable efficacy in this group of people. Overseas literature and practical experience show that some patients can obtain long-term remission, demonstrating the great potential of precision medicine.

However, the use of entrectinib is not completely risk-free. Some patients may experience fatigue, gastrointestinal reactions, or taste changes during treatment. Most of these side effects are controllable, but require physician monitoring and symptomatic treatment. In addition, the tolerance of long-term medication is also a problem that needs attention, so standardized follow-up during treatment is particularly important. Overall, entrectinib provides a breakthrough targeted therapy for patients with ROS1-positive and NTRK fusion lung cancer.

Reference materials:https://www.roche.com/products/rozlytrek